New Jersey Intellectual Property Law Association (NJIPLA)
This webinar intends to provide the background and jurisprudence on the patentability of chemical and pharmaceutical selection inventions. The panel will discuss topics such as novelty, obviousness (or inventive step), and sufficiency of disclosure as it relates to selection inventions and the prior art for which the invention is said to be generically disclosed. Several case examples will be provided and similarities and differences between the US and Europe will be discussed. The discussion will take into account the most recent developments in EPO practice and case law and will review the recent US Federal Circuit decision in Mylan v. Merck.
Earn up to 1.0 Professional CLE for NJ/NY/PA
Member Free | Non-Member $45.00
Dr. Roy Issac, Senior IP Counsel, Bristol Myers Squibb
Dr. M. David Weingarten, Partner, Finnegan, Henderson, Farabow, Garrett &
Dr. Steven M. Zeman, Partner, European and German Patent Attorney, Grünecker Patent- und Rechtsanwälte PartG mbB
Dr. Jegannath Korukottu, European and UK Chartered Patent Attorney, Grünecker Patent- und Rechtsanwälte PartG mbB
Zoom Note: Once you register, you will receive a Zoom confirmation e-mail with a unique link to join the session. Click "Add to calendar" to ensure you don't miss the webinar.
Committee Co-Chairs J. Eric Thies, Organon & Co. and Suja Vathyam, Botos Churchill IP Law LLP